Ignite Creation Date:
2024-05-06 @ 2:43 PM
Last Modification Date:
2024-10-26 @ 1:36 PM
Study NCT ID:
NCT04406649
Status:
COMPLETED
Last Update Posted:
2023-07-03
First Post:
2020-05-20
Brief Title:
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Sponsor:
Satsuma Pharmaceuticals Inc
Organization:
Satsuma Pharmaceuticals Inc
Study Overview
Official Title:
An Open-Label 12-Month Study to Evaluate the Safety and Tolerability of STS101 Dihydroergotamine Nasal Powder in the Acute Treatment of Migraine
Status:
COMPLETED
Status Verified Date:
2023-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ASCEND
Brief Summary:
Study STS101-003 is a multi-center multiple dose PRN open-label 12-month study to evaluate the safety and tolerability of STS101 dihydroergotamine nasal powder in the acute treatment of migraine
Detailed Description:
The ASCEND trial is a multi-center multiple dose PRN open-label 12-month study to evaluate the safety and tolerability of STS101 dihydroergotamine nasal powder in the acute treatment of migraine
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None